Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Murali Aravamudan - aVenture Research

Murali Aravamudan

AddedMar 31, 2024

UpdatedOct 16, 2026

Murali Aravamudan

Murali Aravamudan

Co-Founder & CEO, Qrativ

Murali Aravamudan's Career

TiVo

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

San Jose, CA, US

Co-Founder

Pramana

Series A$30MCambridge, MA, US

Co-Founder

Qrativ

Series A$8.3MCambridge, MA, US

Co-Founder & CEO· C-Suite · Management

Co-Founder

Nference

Series C$152.7MCambridge, MA, US

Co-Founder & CEO· C-Suite · Management

Co-Founder

Anumana

Series C$117.7MCambridge, MA, US

CEO· C-Suite · Management

People Similar to Murali Aravamudan

Sachin H JainBoard Member · Cue Health

Utku PamuksuzCo-Founder · Inference Analytics

Farrukh KhanCo-Founder · Inference Analytics

Naveen SrinivasCo-Founder · AccurKardia

Aaron NeiderhiserFounder · Tuva Health

Wall, DennisFounder · Cognoa

Sharief TaramanCEO · Cognoa

Hui LiCEO · Singularity.AI

Leadership at TiVo

John RyanCo-Founder

Jon KirchnerBoard Member

Paul E. DavisBoard Member

John AllenBoard Member

Similar to TiVo

XperiSan Jose, CA, USMedia Platforms, Softwareest. 1990XperiSan Jose, CA, US · est. 1990

Xperi Inc.: A leading US tech firm specializing in software for consumer electronics, connected cars, and media platforms.

Public · $5.2M2k

Similar to Pramana

Pathology WatchMurray, UT, USDigital Pathologyest. 2018Pathology WatchMurray, UT, US · est. 2018

Pathology Watch offers a user-friendly digital pathology solution for dermatologists.

Series B · $56.7M66

ProsciaPhiladelphia, PA, USDigital Pathology, Informaticsest. 2014ProsciaPhiladelphia, PA, US · est. 2014

A digital pathology platform advancing research and diagnostics towards a data-driven discipline.

Series C · $80.5M100

DigipathLas Vegas, NV, USDigital Pathology, Researchest. 1998DigipathLas Vegas, NV, US · est. 1998

DigiPath, Inc. pioneers in digital pathology solutions, botanical nutraceutical research, and industry training services.

Public · $10.6M13

HistoWizNew York City, NY, USHistology, Pathologyest. 2012HistoWizNew York City, NY, US · est. 2012

HistoWiz: Fast, digital histopathology & global research collaboration to fight cancer.

Series A · $36.8M77

Similar to Qrativ

QbDVisionAustin, TX, USPlatform, Softwareest. 2016QbDVisionAustin, TX, US · est. 2016

QbDVision: A pioneering biopharma platform transforming fragmented data into process intelligence.

Series A · $17M45

Qatch TechnologiesDurham, NC, USBiopharma Toolsest. 2016Qatch TechnologiesDurham, NC, US · est. 2016

QATCH Technologies: Pioneering tools for early-stage injectability and manufacturability assessment in biopharma.

Angel · $766.1k4

QuantumBioState College, PA, USDrug Discovery, Softwareest. 2002QuantumBioState College, PA, US · est. 2002

QuantumBio, based in State College, US, develops innovative drug discovery software for the life science industry.

Seed · $425k14

QI HealthcareCincinnati, OH, USHealthcare Softwareest. 2011QI HealthcareCincinnati, OH, US · est. 2011

QI Healthcare: Enhancing hospital efficiency and outcomes with quality-improvement software.

Leadership at Nference

Venky SoundararajanCo-Founder

Similar to Nference

MithrlSan Francisco, CA, USest. 2023MithrlSan Francisco, CA, US · est. 2023

Mithrl builds AI infrastructure and biomedical world models for biopharma R&D teams.

Series A · $24M24

ScienceIOBoston, MA, USHealthcare Dataest. 2019ScienceIOBoston, MA, US · est. 2019

Healthcare AI firm decoding medical language to unlock untapped data potential.

InsitroSouth San Francisco, CA, USDrug Discoveryest. 2018InsitroSouth San Francisco, CA, US · est. 2018

Insitro: Leveraging machine learning for data-driven drug discovery and development.

Series C · $643M295

Lifebit BiotechLondon, Greater London, GBAnalytics, Data Platformest. 2017Lifebit BiotechLondon, Greater London, GB · est. 2017

Lifebit: A cognitive system provider making biomedical and genomic data accessible and usable.

Series B · $70.6M151

Leadership at Anumana

Zachi AttiaBoard Member

Similar to Anumana

AccurKardiaNew York City, NY, USECG Softwareest. 2019AccurKardiaNew York City, NY, US · est. 2019

AccurKardia: An AI-based cardiac analysis firm offering cloud-based, FDA-cleared ECG interpretation software.

Cardiac InsightBellevue, WA, USMedical Devices, Softwareest. 2010Cardiac InsightBellevue, WA, US · est. 2010

Cardiac Insight: Innovating ECG diagnostics with advanced wearable sensors and automated software.

Public · $32.3M44

MedicalgorithmicsNew York City, NY, USCardiac Monitoring, ECGest. 2005MedicalgorithmicsNew York City, NY, US · est. 2005

Medicalgorithmics: Global leader in cardiac monitoring solutions, innovating with mobile ECG technology.

Public · PLN2M175

HeartioPittsburgh, PA, USDiagnostics, Healthcareest. 2018HeartioPittsburgh, PA, US · est. 2018

HEARTio: A Pittsburgh-based AI startup revolutionizing heart diagnostics since 2018.

OpentvSan Francisco, CA, USDigital TV Softwareest. 1999

OpentvSan Francisco, CA, US · est. 1999

OpenTV provides advanced digital television middleware and multiscreen video software solutions for broadcast and telecommunications operators.

RokuSan Jose, CA, USSmart Tvs, Streaming Devicesest. 2002RokuSan Jose, CA, US · est. 2002

Leading San Jose manufacturer of streaming devices and smart TVs, Roku, Inc. reaches 70M viewers globally.

Public · $22.2B3.6k

ActiveVideo NetworksSan Jose, CA, USVideo Softwareest. 1988ActiveVideo NetworksSan Jose, CA, US · est. 1988

Cloud-based software company revolutionizing TV experience with patented technology.

Public · $87M175